|Mr. Matthew R. Kane||Advisor||733.53k||N/A||1977|
|Dr. Christopher R. Heery||Consultant||587.38k||N/A||1980|
|Mr. Michael Amoroso||Pres, CEO & Director||N/A||N/A||1978|
|Dr. Derek Jantz Ph.D.||Co-Founder, Chief Scientific Officer & Director||N/A||N/A||1976|
|Dr. Jefferson J. Smith Ph.D.||Co-Founder & CTO||N/A||N/A||N/A|
|Mr. John Alexander Kelly||Chief Financial Officer||N/A||N/A||1967|
|Mr. Shane Barton||VP, Corp. Controller & Principal Accounting Officer||N/A||N/A||1971|
|Mr. Dario Scimeca||Gen. Counsel & Sec.||N/A||N/A||1975|
|Mr. Bruce Stevens||VP of Quality & Compliance||N/A||N/A||N/A|
|Ms. Heather King||Director of Marketing Communications & PR||N/A||N/A||N/A|
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; and iECURE to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Precision BioSciences, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 8. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 8; Compensation: 8.